LUP Stock Overview
An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LUP from our risk checks.
Luye Pharma Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.31 |
| 52 Week High | HK$0.46 |
| 52 Week Low | HK$0.28 |
| Beta | 0.75 |
| 11 Month Change | 0% |
| 3 Month Change | -3.09% |
| 1 Year Change | -18.65% |
| 33 Year Change | -38.43% |
| 5 Year Change | -51.32% |
| Change since IPO | -54.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| LUP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.3% | -7.0% | -0.1% |
| 1Y | -18.7% | -19.7% | 2.4% |
Return vs Industry: LUP exceeded the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: LUP underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| LUP volatility | |
|---|---|
| LUP Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: LUP has not had significant price volatility in the past 3 months.
Volatility Over Time: LUP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 5,270 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
| LUP fundamental statistics | |
|---|---|
| Market cap | €1.21b |
| Earnings (TTM) | €68.35m |
| Revenue (TTM) | €788.40m |
17.7x
P/E Ratio1.5x
P/S RatioIs LUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUP income statement (TTM) | |
|---|---|
| Revenue | CN¥6.14b |
| Cost of Revenue | CN¥1.94b |
| Gross Profit | CN¥4.20b |
| Other Expenses | CN¥3.67b |
| Earnings | CN¥532.61m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 68.44% |
| Net Profit Margin | 8.67% |
| Debt/Equity Ratio | 61.7% |
How did LUP perform over the long term?
See historical performance and comparison